Salute e Benessere
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
"We are proud to be showcasing abstracts as part of the ISTH programme, including Doptelet abstracts that present new data related to children living with ITP, Altuvoct outcomes for perioperative management, and joint health outcomes from a long-term extension study, as well as final outcomes from the B-MORE study. Many people living with rare conditions have unmet needs, and we are proud to present additional data advancing treatments for these rare conditions."
Session time: 14:45 - 16:00 EDT
Location: 151 A&B, Walter E.
Washington CC Convention Center
Session time: 14:45 - 16:00 EDT
Location: Ballroom A-C, Walter E.
Washington CC Convention Center
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Session time: 13:45 - 14:45 EDT
Location: Exhibition hall
Session time: 13:45 - 14:45 EDT
Location: Exhibition hall
Session time: 14:45 – 16:00 EDT
All abstracts are accessible through the official ISTH website. However, any late-breaking abstracts will only be made available later.
ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A. ALTUVOCT can be used for all age groups and any disease severity.
Elocta®/Eloctate® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A. Elocta/Eloctate can be used for all age groups.
Alprolix® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B. Alprolix can be used for all age groups.
About Doptelet® (avatrombopag)
Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe , North America , the Middle East , Asia and Australia . In 2024, revenue amounted to SEK 26 billion . Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi's team is guided by one purpose: to chase the miracles of science to improve people's lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi's people and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or ALTUVIIIO in the US, Japan , and Taiwan , and Altuvoct in Europe . Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe , North Africa , Russia , and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-will-showcase-extensive-research-and-clinical-outcomes-at-isth-2025,c4166601
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/sobi-will-showcase-extensive-research-and-clinical-outcomes-at-isth-2025-302486857.html